{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:19:06Z","timestamp":1792293546386,"version":"4.4.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"abstract":"\n Objectives<\/jats:title>\n \n Inoperable or metastatic paragangliomas (PGLs) and malignant pheochromocytomas (PCCs) are rare tumours with limited options for systemic treatment. Aim of this study was to assess the safety and efficacy of the radiolabelled somatostatin analogue (\n 177<\/jats:sup>\n LutetiumDOTA\n 0<\/jats:sup>\n -Tyr\n 3<\/jats:sup>\n )octreotate (\n 177<\/jats:sup>\n Lu-DOTATATE) for the treatment of PGLs and PCCs.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Patients with histologically proven inoperable or malignant PGLs and PCCs treated with\n 177<\/jats:sup>\n Lu-DOTATATE at our centre were retrospectively analysed. Patients were treated with up to four cycles of\n 177<\/jats:sup>\n Lu-DOTATATE with an intended dose of 7.4\u2009Gb per cycle. Response was assessed with use of RECIST 1.1.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Thirty patients were included: 17 with parasympathetic, 10 with sympathetic PGLs and 3 with PCCs. Grade 3\/4 subacute haematotoxicity occurred in 6 (20%) of patients. A reversible subacute adverse event due to cardiac failure following possible catecholamine release occurred in two patients. Best tumour response was partial response in 7 (23%) and stable disease in 20 (67%), whereas 3 (10%) patients had progressive disease. In 20 patients with baseline disease progression, tumour control was observed in 17 (85%); the median progression-free survival was 91 months in patients with parasympathetic PGLs, 13 months in patients with sympathetic PGLs and 10 months in patients with metastatic PCCs.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n This study suggests that PRRT with\n 177<\/jats:sup>\n Lu-DOTATATE is a safe and effective treatment option for patients with inoperable or malignant PGL and PCC.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1530\/eje-18-0901","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T10:44:12Z","timestamp":1557312252000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":73,"title":["Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE"],"prefix":"10.1093","volume":"181","author":[{"given":"Wouter T","family":"Zandee","sequence":"first","affiliation":[{"name":"1Department of Internal Medicine, Sector Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Feelders","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Sector Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan A","family":"Smit Duijzentkunst","sequence":"additional","affiliation":[{"name":"2Department of Radiology & Nuclear Medicine, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Hofland","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Sector Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Mick","family":"Metselaar","sequence":"additional","affiliation":[{"name":"3Department of ENT Surgery, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier A","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"4Department of Clinical Genetics, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"van Linge","sequence":"additional","affiliation":[{"name":"3Department of ENT Surgery, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boen L R","family":"Kam","sequence":"additional","affiliation":[{"name":"2Department of Radiology & Nuclear Medicine, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap J M","family":"Teunissen","sequence":"additional","affiliation":[{"name":"2Department of Radiology & Nuclear Medicine, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Korpershoek","sequence":"additional","affiliation":[{"name":"5Department of Pathology, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M","family":"Hendriks","sequence":"additional","affiliation":[{"name":"6Department of Surgery, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huda","family":"Abusaris","sequence":"additional","affiliation":[{"name":"7Department of Radiation Oncology, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleo","family":"Slagter","sequence":"additional","affiliation":[{"name":"7Department of Radiation Oncology, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston J H","family":"Franssen","sequence":"additional","affiliation":[{"name":"6Department of Surgery, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Brabander","sequence":"additional","affiliation":[{"name":"2Department of Radiology & Nuclear Medicine, ENETS Centre of Excellence, Erasmus University Medical Center and Erasmus MC Cancer Institute, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter W","family":"De Herder","sequence":"additional","affiliation":[{"name":"1Department of Internal Medicine, Sector Endocrinology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/181\/1\/EJE-18-0901.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/181\/1\/EJE-18-0901.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T11:12:47Z","timestamp":1676373167000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/181\/1\/45\/6654181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":0,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/eje-18-0901","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}